<DOC>
	<DOCNO>NCT02237690</DOCNO>
	<brief_summary>This multi-center , single-dose , open-label , randomize , balance , two-treatment , two-cycle , two-sequence crossover study assess bioequivalence test ( T ) reference ( R ) formulation doxorubicin hydrochloride liposome injection female patient ovarian cancer . Each patient randomize one two treatment sequence ( RT TR ) accord randomization scheme prepare prior start trial.There least 4-week apart single-dose administration . Serial blood sample determination free doxorubicin liposomal encapsulate doxorubicin plasma concentration PK analysis obtain cycle . The 90 % confidence interval GMR ( geometric mean ratio ) test reference product free liposome encapsulate doxorubicin PK must within 80-125 % demonstrate bioequivalence .</brief_summary>
	<brief_title>Assess Bioequivalence Two Formulations Doxorubicin Hydrochloride Liposome Female Patients With Ovarian Cancer</brief_title>
	<detailed_description>This study adaptive 2-stage design . Bioequivalence base encapsulate doxorubicin test end Stage 1 . An interim analysis free doxorubicin perform end Stage 1 . If need , study may continue Stage 2 additional number ovarian cancer patient determine base interim analysis ; final evaluation bioequivalence free doxorubicin perform end Stage 2 . Each patient randomize one two treatment sequence ( RT TR ) accord randomization scheme prepare prior start trial . Serial blood sample determination free doxorubicin liposomal encapsulate doxorubicin plasma concentration PK analysis obtain cycle . The 90 % confidence interval GMR（geometric mean ratio） test reference product free liposome encapsulate doxorubicin PK must within 80-125 % demonstrate bioequivalence . Safety data summarize list . Adverse event cod classified system organ class preferred term use Common Terminology Criteria Adverse Events . A summary drug-related adverse event also generate . Clinical laboratory data summarize descriptively list treatment group . The change pre dose end study also summarize . Prior concomitant medication cod World Health Organization Drug Dictionary list . Vital sign electrocardiogram data summarize list dose group visit .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Able give write informed consent participation trial ; Females age 18 75 year , inclusive ; Histologically cytologically proven ovarian cancer , progress recur CT/MRI confirmation platinumbased chemotherapy ; ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 2 ; Patient expect able receive dos Doxorubicin Hydrochloride Liposome Injection participate trial least 56 day . Urine pregnancy test dose cycle1 cycle 2 must negative ( include postmenopausal surgically sterile woman ) ; Agree use approve method birth control ( condom spermicide , diaphragm cervical cap spermicide , intrauterine device ) ; patient nonchildbearing potential either surgically sterile ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) &gt; 1 year postmenopausal folliclestimulating hormone postmenopausal range ; 30days 5 halflives ( whichever longer ) elapse completion previous cancer therapy , patient must recover &lt; Grade 2 new stable baseline related toxicity ; Adequate renal , hepatic bone marrow function without blood product hematopoietic growth factor support : Able comply study requirement opinion Principal Investigator Significant allergy , hypersensitivity idiosyncratic reaction doxorubicin and/or related compound ; History presence cardiac disease rat New York State Heart Association Classification class 2 great ; Uncontrolled cardiac arrhythmia finding screen electrocardiogram ( ECG ) could , judgment Principal Investigator , put patient undue risk participation trial ; LVEF（left ventricular ejection fraction） 50 % institutional normal screening ; Prior radiation therapy mediastinum ; Concomitant use cytotoxic cytostatic drug radiotherapy ; Active , uncontrolled infection , include opportunistic infection mycobacteria , cytomegalovirus , toxoplasma , P. carinii ; Use prescription nonprescription herbal dietary supplement , within 7 day 5 halflives ( whichever longer ) prior first dose study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>